News | Nuclear Imaging | November 07, 2018

MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine

New market report notes that approximately $10 billion in M&A transactions have occurred over the past four years, with signs indicating continuing future growth

MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine

November 7, 2018 — With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry towards radiopharmaceuticals and in particular radiotherapeutics and radiotheranostics is clearly growing, as foreseen a few years ago by MEDraysintell.

Numerous major acquisitions have involved the conventional pharmaceutical industry over the past four years:

  • In 2014, Bayer acquired Algeta ASA and its major drug for end-stage prostate cancer treatment 223Ra-Xofigo for about NOK 17.6 billion ($2.9 billion), while Novartis took over Advanced Accelerator Applications (AAA) and its Neuro Endocrine Tumor treatment 177Lu-Lutathera in January 2018 for a total value of $3.9 billion;
  • Additionally Novartis announced in October 2018 the acquisition of the company Endocyte developing the prostate cancer drug 177Lu-PSMA-617 for a total value of $2.1 billion. This transaction is expected to be completed in the first half of 2019.
  • Ipsen Pharma acquired in May 2015 the German company OctreoPharm Sciences GmbH, for a total of EUR 50 million (about $55 million) and one year later a large part of the radiopharmaceutical pipeline of the German company 3B Pharmaceuticals GmbH; and
  • Sun Pharmaceutical Industries acquired Pharmalucence in July 2014 for an undisclosed amount.

MEDraysintell noted that other mergers within the radiopharmaceutical industry showed consolidation of this industry:

  • IBA Molecular acquired the Nuclear Medicine business of Mallinckrodt in January 2017 for a total of about $690 million;
  • Jubilant Draximage acquired the Triad Isotopes radiopharmacy network in May 2017; and
  • Sofie Biosciences took over Zevacor Pharma in May 2017.

The company said there are great chances that additional mergers and acquisitions (M&A) will take place within the next 12 months. At the same time, the conventional pharmaceutical industry is now looking for new opportunities in early-stage research programs in this area. MEDraysintell anticipates that the global market will reach $5.9 billion in 2019, and it is now expected that radiotherapeutics will represent more than 60 percent of the $26 billion nuclear medicine market by 2030.

Most of the development of new radiopharmaceuticals is performed by new medium-sized radiopharmaceuticals companies and conventional pharmaceutical corporations. MEDraysintell said these companies are extensively covered in the new Nuclear Medicine Report & Directory, Edition 2018.

For more information: www.medraysintell.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
Potassium Molybdate Mo 99 Source Vessels for RadioGenix System

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | February 18, 2020
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a
SIR-Spheres Y-90 resin

SIR-Spheres Y-90 resin microspheres are released into the hepatic artery.

News | Nuclear Imaging | February 14, 2020
February 14, 2020 —  ...
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...